111 related articles for article (PubMed ID: 26226845)
41. Insights into pediatric rhabdomyosarcoma research: Challenges and goals.
Yohe ME; Heske CM; Stewart E; Adamson PC; Ahmed N; Antonescu CR; Chen E; Collins N; Ehrlich A; Galindo RL; Gryder BE; Hahn H; Hammond S; Hatley ME; Hawkins DS; Hayes MN; Hayes-Jordan A; Helman LJ; Hettmer S; Ignatius MS; Keller C; Khan J; Kirsch DG; Linardic CM; Lupo PJ; Rota R; Shern JF; Shipley J; Sindiri S; Tapscott SJ; Vakoc CR; Wexler LH; Langenau DM
Pediatr Blood Cancer; 2019 Oct; 66(10):e27869. PubMed ID: 31222885
[TBL] [Abstract][Full Text] [Related]
42. The histone deacetylase inhibitor Suberoylanilide Hydroxamic Acid (SAHA) as a therapeutic agent in rhabdomyosarcoma.
Ghayad SE; Rammal G; Sarkis O; Basma H; Ghamloush F; Fahs A; Karam M; Harajli M; Rabeh W; Mouawad JE; Zalzali H; Saab R
Cancer Biol Ther; 2019; 20(3):272-283. PubMed ID: 30307360
[TBL] [Abstract][Full Text] [Related]
43. Data-driven human transcriptomic modules determined by independent component analysis.
Zhou W; Altman RB
BMC Bioinformatics; 2018 Sep; 19(1):327. PubMed ID: 30223787
[TBL] [Abstract][Full Text] [Related]
44. Integrative Bayesian Analysis Identifies Rhabdomyosarcoma Disease Genes.
Xu L; Zheng Y; Liu J; Rakheja D; Singleterry S; Laetsch TW; Shern JF; Khan J; Triche TJ; Hawkins DS; Amatruda JF; Skapek SX
Cell Rep; 2018 Jul; 24(1):238-251. PubMed ID: 29972784
[TBL] [Abstract][Full Text] [Related]
45. NELL1, whose high expression correlates with negative outcomes, has different methylation patterns in alveolar and embryonal rhabdomyosarcoma.
Tombolan L; Poli E; Martini P; Zin A; Romualdi C; Bisogno G; Lanfranchi G
Oncotarget; 2017 May; 8(20):33086-33099. PubMed ID: 28380437
[TBL] [Abstract][Full Text] [Related]
46. Global DNA methylation profiling uncovers distinct methylation patterns of protocadherin alpha4 in metastatic and non-metastatic rhabdomyosarcoma.
Tombolan L; Poli E; Martini P; Zin A; Millino C; Pacchioni B; Celegato B; Bisogno G; Romualdi C; Rosolen A; Lanfranchi G
BMC Cancer; 2016 Nov; 16(1):886. PubMed ID: 27842508
[TBL] [Abstract][Full Text] [Related]
47. DNMT3B in vitro knocking-down is able to reverse embryonal rhabdomyosarcoma cell phenotype through inhibition of proliferation and induction of myogenic differentiation.
Megiorni F; Camero S; Ceccarelli S; McDowell HP; Mannarino O; Marampon F; Pizer B; Shukla R; Pizzuti A; Marchese C; Clerico A; Dominici C
Oncotarget; 2016 Nov; 7(48):79342-79356. PubMed ID: 27764816
[TBL] [Abstract][Full Text] [Related]
48. Advances in sarcoma diagnostics and treatment.
Dancsok AR; Asleh-Aburaya K; Nielsen TO
Oncotarget; 2017 Jan; 8(4):7068-7093. PubMed ID: 27732970
[TBL] [Abstract][Full Text] [Related]
49. PAX3-FOXO1 fusion gene in rhabdomyosarcoma.
Linardic CM
Cancer Lett; 2008 Oct; 270(1):10-8. PubMed ID: 18457914
[TBL] [Abstract][Full Text] [Related]
50. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma.
Barr FG
Oncogene; 2001 Sep; 20(40):5736-46. PubMed ID: 11607823
[TBL] [Abstract][Full Text] [Related]
51. Distinct methylation profiles characterize fusion-positive and fusion-negative rhabdomyosarcoma.
Sun W; Chatterjee B; Wang Y; Stevenson HS; Edelman DC; Meltzer PS; Barr FG
Mod Pathol; 2015 Sep; 28(9):1214-24. PubMed ID: 26226845
[TBL] [Abstract][Full Text] [Related]
52. Relationship of DNA methylation to mutational changes and transcriptional organization in fusion-positive and fusion-negative rhabdomyosarcoma.
Sun W; Chatterjee B; Shern JF; Patidar R; Song Y; Wang Y; Walker RL; Pawel BR; Linardic CM; Houghton P; Hewitt SM; Edelman DC; Khan J; Meltzer PS; Barr FG
Int J Cancer; 2019 Jun; 144(11):2707-2717. PubMed ID: 30565669
[TBL] [Abstract][Full Text] [Related]
53. Gene Co-Expression Networks Restructured Gene Fusion in Rhabdomyosarcoma Cancers.
Helm BR; Zhan X; Pandya PH; Murray ME; Pollok KE; Renbarger JL; Ferguson MJ; Han Z; Ni D; Zhang J; Huang K
Genes (Basel); 2019 Aug; 10(9):. PubMed ID: 31480361
[TBL] [Abstract][Full Text] [Related]
54. Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas.
Laé M; Ahn EH; Mercado GE; Chuai S; Edgar M; Pawel BR; Olshen A; Barr FG; Ladanyi M
J Pathol; 2007 Jun; 212(2):143-51. PubMed ID: 17471488
[TBL] [Abstract][Full Text] [Related]
55. JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells.
Walters ZS; Villarejo-Balcells B; Olmos D; Buist TW; Missiaglia E; Allen R; Al-Lazikani B; Garrett MD; Blagg J; Shipley J
Oncogene; 2014 Feb; 33(9):1148-57. PubMed ID: 23435416
[TBL] [Abstract][Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
